HK Stock Market Move | CHINARES PHARMA (03320) rose nearly 8% after the performance results. Annual net profit attributable to shareholders increased by 20.73% year-on-year. Revenue growth exceeded industry average levels.

CHINARES PHARMA (03320) rose nearly 8% after earnings, and as of the time of writing, it had risen 7.64% to HK$4.78, with a trading volume of HK$338.24 million. On the news front, on March 24th, CHINARES PHARMA released its annual results for the year ending December 31, 2025. The group's revenue was RMB 269.574 billion, a year-on-year increase of 4.62%; shareholder's profit attributable to equity holders was RMB 4.045 billion, a year-on-year increase of 20.73%; earnings per share were 0.64 yuan; and a final dividend of 0.122 yuan. Against the backdrop of intensified competition and downward pressure in the pharmaceutical industry, the group's revenue and profit achieved double-digit growth in 2025, and its income growth rate during the "14th Five-Year Plan" period exceeded the industry average. During the reporting period, the group's brands received significant recognition. China Resources Sanjiu Medical & Pharmaceutical won the first prize of the National Ministry of Education's award for outstanding scientific research achievements, and it was rated as the highest level "benchmark" by the State-owned Assets Supervision and Administration Commission of the State Council for three consecutive years; "Jiangzhong" and "Dong-E-E-Jiao" were selected for the first batch of China Consumer Brands List by the Ministry of Industry and Information Technology; China Resources Double-Crane Pharmaceutical's subsidiary was honored as an "excellent case of national health enterprise construction"; China Resources Sanjiu Medical & Pharmaceutical, China Resources Double-Crane Pharmaceutical, China Resources Jiangzhong Pharmaceutical, and Dong-E-E-Jiao were jointly selected for the "excellent level intelligent factory" by the Ministry of Industry and Information Technology, showcasing the group's multi-level, multi-dimensional brand influence.